Sidnei Epelman, M.D. Director – INCTR Brazil Including Mozambique in INCTR’s sub-Saharan African Network for the treatment of Lymphoma Including Mozambique.

Slides:



Advertisements
Similar presentations
HIV TB. World wide TB is the most common cause of death in people with HIV About 1/3 of HIV infected people worldwide are co-infected with TB (co-infection.
Advertisements

Confidential and Proprietary Information © 2011 Express Scripts, Inc. All Rights Reserved 1 The State of New Mexico Prescription Drug Program 2013.
Background/Purpose ATRT is a rare and aggressive CNS tumor usually presenting in very young children (age less than 5 years). Aggressive treatments have.
Who, What and When: Transplant for Acute Lymphoblastic Leukemia Brandon Hayes-Lattin September 13, 2013.
Childhood Cancers: A Review Haruna Baba Jibril MB,BS; FCMPaed; MSc (Haem) Department of Pediatrics Princess Marina Hospital.
Dr N M Butt Consultant Haematologist
Oncologic Drugs Advisory Committee
IN ACUTE MYELOID LEUKEMIA, THE USE IN INDUCTION OF STANDARD DOSE ARA-C IS ASSOCIATED WITH A BETTER QUALITY OF RESPONSE AS COMPARED TO AN INDUCTION REGIMEN.
Relapse in Children with ALL By Dr Kaji Protocol for Acute Lymphoblastic Leukemia Relapse IN LANZKOWSKY.
The Pediatric Perspective on Cancer Survivorship Sue Lindemulder, MD, MCR Medical Director, Childhood Cancer Survivorship Program September 12, 2013.
WHO supported Injury Surveillance in Africa Dr. Olive C. Kobusingye, WHO/AFRO Ms. Kidist Bartolomeos, WHO Mozambique Ms. Malin Ahrne, WHO Ethiopia Dr.
South-South Cooperation Programme for the Right to Education in Lusophone Countries.
Delivery of Intrathecal Chemotherapy Kowloon Central Cluster 10Jan08.
Improving Diagnosis and Management of Hypertension: Implementation of Ambulatory Blood Pressure Monitoring in Primary Care* Scot B. Sternberg, MS; Kristine.
Presented at the Arthritis Advisory Committee on July 15, 2003 by Naomi Winick, M.D.
Continuous Quality Improvement – Knowledge Management by Any Other Name Peter Hobby Director of Communications and KM Center for Pharmaceutical Management.
Purposes and uses of cancer registration E.E.U. Akang Department of Pathology University College Hospital Ibadan, Nigeria.
Medical Research BADRAG meeting Jan 2013 Dr H Sari-Kouzel.
THANK YOU!. Regional Adviser, Noncommunicable Diseases, WHO/EMRO Dr Ibtihal Fadhil.
Patients on Chemotherapy Dr. Feras FARARJEH. General Concepts The purpose of treating cancer with chemotherapeutic agents is to prevent cancer cells from.
Up-Front Phase II Windows in Children with Cancer Victor M. Santana, M.D.
Childhood cancer in Africa French African Pediatric Oncology Group experience Mhamed Harif CHU Mohammed VI, Marrakech, Morocco
Follicular & Aggressive B-Cell Lymphomas. Five-year TTF and Response Duration (RD) According to FLIPI Risk Group R-CHOPCHOPP value TTF Low-risk
Africa – A Challenge Slides and charts prepared by Chris Maynard based on data in “Atlas of Global Christianity” 2010 Center for the Study of.
ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP inhibitor, Niraparib and Temozolomide in Patients with Previously Treated,
Background Diffuse large B-cell lymphoma (DLBCL) is the most commonly occurring lymphoma in the Western world. It’s account for about one-third of all.
California Stroke Registry Right Care Initiative Meeting August 13, 2012.
Implementing the revised TB/HIV indicators and data harmonisation at country level Christian Gunneberg MO WHO Planning workshop to accelerate the implementation.
Acknowledgements Natalie Weir, for help with the charts. Conclusion Toxicities were broadly as expected and interestingly, most care issues were associated.
C-1 Pegfilgrastim (Neulasta  ) Oncologic Drugs Advisory Committee Pediatric Subcommittee October 20, 2005 Amgen Inc.
Leukaemia for shared care centres Workshop session Caroline Osborne & Julia Hitchin (Alder Hey) NPPG conference 11 th November 2012.
Journal Club Dr. Eyad Al-Saeed Radiation Oncology 12 January, 2008.
PREPARED BY Cancer Programme Work Programme 2012/13.
미 국 에 서 의 병 원 약 사 의 역 할 서 옥 경, Pharm.D. 서울대학교 약학대학.
Gynaecological Oncology Patient Pathway Cecile Bergzoll Gynaecological Oncologist Wellington.
Patterns of care and comparative effectiveness of endocrine therapy for premenopausal women with early breast cancer A multi-institution cohort study February.
MethodsAbstract Objectives Results Conclusions References 1.UNGASS UN General Assembly; Sixty-sixth session. 2.Williams, CKO, et al: Eur.J.Cancer.
Blood 2011, 117: R1 Seon-Hye Kim Arnaud Jaccarda and Olivier Hermine Journal conference.
Proton Therapy Patterns-of-Care and Early Outcomes for Hodgkin Lymphoma: Results from the Proton Collaborative Group Registry Bradford Hoppe MD, MPH William.
Lautoka Paedaitric Oncology Services
Description of Tools pharmaceutical care in Acute Lymphoblastic Leukemia (Pharmacogenomics) Hospital Pediatric Experience Chilean Program Associated   with.
African Thoracic and cardiovascular surgeons storms Nigeria for the first time.
Evaluation of CD19 specific Chimeric Antigen Receptor T cells (CAR19 T-cells) as an optimal bridge to allogeneic transplantation. Phase I trial for patients.
Non-Hodgkin’s Lymphoma
Pediatric Oncology Care in Tanzania:
BREAST CANCER IN SETTING OF HIGH HIV PREVALENCE
NCI 9177: Risk-Adapted DA-EPOCH-R in Adults With Burkitt Lymphoma
Same patient as in Fig The computed tomography positron emission tomography scan after four courses of hyperfractionated cyclophosphamide, vincristine,
TB- HIV Collaborative activities in Romania- may 2006 status
1st International Online BioMedical Conference (IOBMC 2015)
Director Department of Pediatric Hematology & Oncology Delhi, INDIA.
Overview of Paediatric Oncology in Malawi
Algorithm for treatment of relapsed aggressive lymphomas (except high-grade or mantle cell lymphoma). MINE, mesna, ifosfamide, mitoxantrone, etoposide.
Response to chemotherapy
A-I. MD Anderson Cancer Center algorithms for Hodgkin lymphoma
Communication Skills Lecture 1-2
KEY CONCEPT Genetics provides a basis for new medical treatments.
Key issues in DOTS implementation
Tit Albreht | Brussels | 7 November 2017
KEY CONCEPT Genetics provides a basis for new medical treatments.
KEY CONCEPT Genetics provides a basis for new medical treatments.
Introduction to poster session and discussion
KEY CONCEPT Genetics provides a basis for new medical treatments.
KEY CONCEPT Genetics provides a basis for new medical treatments.
Sources of health outcomes data used in the SJLIFE study where severity grading criteria of long-term and late-onset health events were applied. Sources.
KEY CONCEPT Genetics provides a basis for new medical treatments.
Bradford Hoppe MD, MPH William Hartsell, MD
Presentation transcript:

Sidnei Epelman, M.D. Director – INCTR Brazil Including Mozambique in INCTR’s sub-Saharan African Network for the treatment of Lymphoma Including Mozambique in INCTR’s Sub-Saharan African Network for the treatment of Lymphoma Sidnei Epelman, M.D.

Director – INCTR Brazil Including Mozambique in INCTR’s sub-Saharan African Network for the treatment of Lymphoma Burkitt´s Belt

Sidnei Epelman, M.D. Director – INCTR Brazil Including Mozambique in INCTR’s sub-Saharan African Network for the treatment of Lymphoma BL Study 5 participants centers in 4 sub-Saharan African countries – Kenya – Nigeria – Tanzania – Uganda Purpose – Characterize presentation features of BL – Assess response and treatment outcome

Sidnei Epelman, M.D. Director – INCTR Brazil Including Mozambique in INCTR’s sub-Saharan African Network for the treatment of Lymphoma Study objectives Primary – Characterize presentation features of Burkitt’s Lymphoma in African countries – Assess response, EFS, DFS and OS – Characterize pattern of CNS disease and relapse – Assess toxicities to the regimen Secondary – Pattern of gene expression in African BL – Assess levels of sEBV DNA and correlate with clinican features and response to therapy

Sidnei Epelman, M.D. Director – INCTR Brazil Including Mozambique in INCTR’s sub-Saharan African Network for the treatment of Lymphoma First-Line Treatment Treatment Groups Low Risk Group Patients with a single extra-abdominal tumor of less than 10 cm in size, in its widest diameter. High Risk Group All patients who do not meet the definition of low risk.

Sidnei Epelman, M.D. Director – INCTR Brazil Including Mozambique in INCTR’s sub-Saharan African Network for the treatment of Lymphoma First-Line Treatment Low Risk Group Day 1 Vincristine 1.4 mg/m2 h IV Day 1 Cyclophosphamide 1200 mg/m2 IV Day 1 Methotrexate 75 mg/m2 IV Day 1 Methotrexate intrathecal (IT) Day 4 Cytarabine IT Day 8 Methotrexate IT Total of 3 cycles of therapy. Every 14 days

Sidnei Epelman, M.D. Director – INCTR Brazil Including Mozambique in INCTR’s sub-Saharan African Network for the treatment of Lymphoma First-Line Treatment High Risk Group Day 1 Vincristine 1.4 mg/m2, Day 1 Cyclophosphamide 1200 mg/m2 IV Day 1 Methotrexate 75 mg/m2, IV Day 1 Methotrexate intrathecal Day 4 Cytarabine IT Day 8 Methotrexate IT Total of 6 cycles of therapy Every 14 days CNS TREATMENT High risk patients without CNS disease – as above during the first 3 cycles of therapy. High risk patient with CNS disease - as described above during all 6 cycles of therapy.

Sidnei Epelman, M.D. Director – INCTR Brazil Including Mozambique in INCTR’s sub-Saharan African Network for the treatment of Lymphoma Second-line Treatment Days 1-3 Etoposide 60 mg/m2 IV Days 1-3 Ifosfamide 1500 mg/m2 IV Days 1-3 Mesna 300 mg/m2 IV mixed with ifosfamide and then 300 mg/m2 mesna Injection for 3 additional doses at hours 3, 6 and 9 post ifosfamide.. Days 1-3 Cytarabine 100 mg/m2 IV Day 1 Methotrexate IT Day 4 Cytarabine IT Day 8 Methotrexate IT Total of 6 cycles of therapy Every 14 days

Sidnei Epelman, M.D. Director – INCTR Brazil Including Mozambique in INCTR’s sub-Saharan African Network for the treatment of Lymphoma Supported from INCTR Drugs Data management – Data base – Registration – Monitoring for errors – Assistance with analysis of data Consultation in specific cases when needed Training and Education in Santa Marcelina - SP

Sidnei Epelman, M.D. Director – INCTR Brazil Including Mozambique in INCTR’s sub-Saharan African Network for the treatment of Lymphoma Cost-effective treatment

Sidnei Epelman, M.D. Director – INCTR Brazil Including Mozambique in INCTR’s sub-Saharan African Network for the treatment of Lymphoma Mozambique Participation Dr Joseph Ferro – Pathologist – Registry of Breira Cancer Hospital in Maputo

Sidnei Epelman, M.D. Director – INCTR Brazil Including Mozambique in INCTR’s sub-Saharan African Network for the treatment of Lymphoma On going Programms in Lusophone Africa Development of the program for early diagnosis in Retinoblastoma - all materials (video, posters, cards, etc) are already in Portuguese and Swahili. Implementation of Palliative Care Program - PAX program - (education and training can be provided at Santa Marcelina Hospital ) Development of Protocol for Burkitt´s lymphoma (results will presented by Melissa Adde) Training and Education in Pediatric Oncology at Santa Marcelina Hospital in Sao Paulo - fellow from Angola Raising funds (e.g, concert in London)

Sidnei Epelman, M.D. Director – INCTR Brazil Including Mozambique in INCTR’s sub-Saharan African Network for the treatment of Lymphoma Retinoblastoma video in Swahili